Assessment of Platelet Storage Lesion(PSL)in Platelet Concentrates

Not yet recruiting

• Conditions: Platelet Storage Lesion(PSL)

• Registration Number: NCT05144074
• Lead Sponsor: Assiut University

Brief Summary

The aim of this study to assess platelet activation during 5 days storage of platelet concentrates prepared by different techinques .

Detailed Description

Platelet transfusion is a lifesaving procedure that is carried out to prevent bleeding or stop ongoing bleeding in patients with low platelet count or functional platelet disorders. There are minimum thresholds at which platelets are transfused in these patients, as not all low levels of platelet warrants a transfusion. Platelet is a scarce resource as processing, preparing, and transfusing it requires a great deal of precision and effort to maintain a certain quality. This activity highlights the use of platelet transfusion by the interprofessional team (1).

Platelets play an integral role in hemostasis by its response to vascular injury. The relevance of platelet component therapy was better understood in the 1950s and 1960s when severe and fatal hemorrhagic complications of chemotherapy in leukemia were studied

The collected blood units were randomly assigned to two groups:

1. Non-filtered platelet concentrates (NF-PC group).

2. leukocyte-depleted platelet concentrates (LD-PC group). P-selectin (CD62p) is a type of glycoprotein stored in the Weibel-Palade bodies of vascular endothelial cells and platelet α-granules. Activated CD62P is a transmembrane protein expressed on the platelet surface. During platelet activation, the expression of CD62P on the surface of the cell membrane is dramatically increased in PCs without leukocyte depletion, due to the presence of WBCs and cytokines ,and is accompanied by an increase in the expression level of plasma soluble CD62

Study Timeline

• Status Verified: 2021-11
• Study First Submitted: 2021-11-21
• Study Start: 2021-12-01
• Study First Submitted QC: 2021-12-02
• Last Update Submitted: 2021-12-02
• Study First Posted: 2021-12-03
• Last Update Posted: 2021-12-03
• Primary Completion: 2024-12-01
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

• Donors who met criteria of Egyptian National Transfusion services
• Donors who had not taken any antiplatelet drugs for two weeks prior to donation
• pre-collection platelet count ≥200×109 /L.
• Blood grouping.
• Serological assays for all blood donors (HBsAgs, HCV antibodies, HIV Ag/Ab Syphilis antibodies) on Architect i 2000 SR or Centaur XPT (chemoluminescence).

Exclusion Criteria

• Donors who not met criteria of Egyptian National Transfusion services
• Donors who had taken any antiplatelet drugs for two weeks prior to donation
• pre-collection platelet count <200×109 /L.
• Reactive serology

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
assess platelet activation .	baseline	assess platelet activation during 5 days storage of platelet concentrates prepared by different techinques .

Secondary Outcome Measures

Name	Time	Method
CD62p assessment .	baseline	CD62p assessment of platelet storage lesion(PSL)in platelet concentrates .